CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-04 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −3,300 | $15.38 | $51K | 44,214 |
| 2026-11-04 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −1,469 | $16.20 | $24K | 42,745 |
| 2026-11-03 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −6,113 | $25.83 | $158K | 4,406 |
| 2026-11-02 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +5,786 | $8.72 | $50K | 21,121 |
| 2026-11-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −9,527 | $25.74 | $245K | 11,594 |
| 2026-11-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −1,075 | $26.76 | $29K | 10,519 |
| 2026-11-02 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,786 | 105,465 | ||
| 2026-11-02 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +1,452 | $1.86 | $3K | 124,904 |
| 2026-11-02 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −1,452 | $26.80 | $39K | 123,452 |
| 2026-11-02 | Hansen Gwenn Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,452 | 57,954 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,750 | 43,916 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,859 | 46,775 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,573 | 50,348 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Sale | −2,834 | $26.28 | $74K | 47,514 |
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −3,750 | 7,500 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,859 | 17,150 | ||
| 2026-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −3,573 | 35,730 | ||
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise | +3,750 | 12,860 | ||
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise | +2,859 | 15,719 | ||
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise | +3,573 | 19,292 |
Page 1 of 20 · 381 trades